Selective interaction of lansoprazole and astemizole with tau polymers: potential new clinical use in diagnosis of Alzheimer's disease - Test2 - elhamkhani - TriplyDB

Selective interaction of lansoprazole and astemizole with tau polymers: potential new clinical use in diagnosis of Alzheimer's disease

Selective interaction of lansoprazole and astemizole with tau polymers: potential new clinical use in diagnosis of Alzheimer's disease

http://www.wikidata.org/entity/Q24633911

about

Invited review: Frontotemporal dementia caused by microtubule-associated protein tau gene (MAPT) mutations: a chameleon for neuropathology and neuroimaging High affinity radiopharmaceuticals based upon lansoprazole for PET imaging of aggregated tau in Alzheimer's disease and progressive supranuclear palsy: synthesis, preclinical evaluation, and lead selection Defensive effect of lansoprazole in dementia of AD type in mice exposed to streptozotocin and cholesterol enriched diet Drug Repositioning for Cancer Therapy Based on Large-Scale Drug-Induced Transcriptional Signatures Dementia, Preclinical Studies in Neurodegeneration and its Potential for Translational Medicine in South America Comparison of New Tau PET-Tracer Candidates With [18F]T808 and [18F]T807 Unique drug screening approach for prion diseases identifies tacrolimus and astemizole as antiprion agents Frequent and symmetric deposition of misfolded tau oligomers within presynaptic and postsynaptic terminals in Alzheimer's disease.Evaluation of [(11)C]N-Methyl Lansoprazole as a Radiopharmaceutical for PET Imaging of Tau Neurofibrillary Tangles.The proton-pump inhibitor lansoprazole enhances amyloid beta production.Tau PET imaging: present and future directions.Advances in tau-based drug discovery.The Co-chaperone BAG2 Mediates Cold-Induced Accumulation of Phosphorylated Tau in SH-SY5Y Cells.PET Radioligands for Imaging of Tau Pathology: Current Status.Risk of dementia from proton pump inhibitor use in Asian population: A nationwide cohort study in Taiwan.Ligand electronic properties modulate tau filament binding site density Proton Pump Inhibitors and Risk of Mild Cognitive Impairment and Dementia.Non human primate models for Alzheimer's disease-related research and drug discovery.Proton pump inhibition increases rapid eye movement sleep in the rat.Development of tau PET Imaging Ligands and their Utility in Preclinical and Clinical Studies.Novel PET/SPECT probes for imaging of tau in Alzheimer's disease.Proton Pump Inhibitors and Dementia: Physiopathological Mechanisms and Clinical Consequences.

P2860

Q27020981-1CFD0EF9-026E-4ED3-BC5C-C13769E96546 Q28241366-CEC9B547-128F-40DB-B6E4-D7089C14F655 Q28535014-31B7BEDB-9FD2-4993-AF51-92FB558661DE Q28550603-EB27EF8D-C461-4E54-8D63-3B1E6CA4F7D2 Q28817091-02BB5463-9A1C-49D2-9CE8-DC7EA0B399AC Q33795224-64582893-0C38-4085-8009-C0366043DA72 Q34036311-524C5234-D99F-4EF2-898E-0DB4A210FAB2 Q34402143-33C9F3A6-D353-47D5-9AF3-866724D54916 Q34423050-697965BE-D552-4BE1-B3F2-090D1A188E4E Q34631939-A8EFFE6C-FB36-4AB7-8154-F1EE69DA6E3C Q34680852-F2CB73B0-D09D-45CE-AF2D-A7218B9ACEA0 Q35321539-C7B9419A-AD65-4B25-AE4B-2D9B074DC91E Q35712546-5E8DA370-3E71-4A53-A9DF-F873BC47745B Q36241261-D79B4D63-C0D3-4863-98A5-BF1FF1EA0791 Q36281192-2F894BFD-C849-4746-98B6-32E3A72E3315 Q36368413-CC999351-D9F8-44A1-B7F6-C024221F29B6 Q38738847-45734500-76E6-4CE1-B8DB-4AABE8836E47 Q38783343-92B77C8D-F69D-49C1-B878-107F83ABF00F Q42413703-4DA3CDC9-0B87-49DA-92FC-CAD3DB9109EE Q47824973-9BBAEFD9-8387-482E-8C65-7324FC8319C1 Q53014962-E380C769-98D4-46A0-8784-ADD274352786 Q55362855-6B48EEAA-F664-4033-9EFF-C43EF178AAC7

P2860

Selective interaction of lansoprazole and astemizole with tau polymers: potential new clinical use in diagnosis of Alzheimer's disease

http://www.wikidata.org/entity/Q24633911

description

2010 nî lūn-bûn

@nan

2010 թուականին հրատարակուած գիտական յօդուած

@hyw

2010 թվականին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Selective interaction of lanso ...... agnosis of Alzheimer's disease

@ast

Selective interaction of lanso ...... agnosis of Alzheimer's disease

@en

Selective interaction of lanso ...... agnosis of Alzheimer's disease

@nl

type

label

Selective interaction of lanso ...... agnosis of Alzheimer's disease

@ast

Selective interaction of lanso ...... agnosis of Alzheimer's disease

@en

Selective interaction of lanso ...... agnosis of Alzheimer's disease

@nl

prefLabel

Selective interaction of lanso ...... agnosis of Alzheimer's disease

@ast

Selective interaction of lanso ...... agnosis of Alzheimer's disease

@en

Selective interaction of lanso ...... agnosis of Alzheimer's disease

@nl

P1433

Q24633911-A6E85FCB-6C7C-45BC-ADB3-59FFA892860B

P1476

Q24633911-BDF15693-C932-4677-9BD5-F4B2FB0F3C5F

P2093

Q24633911-1B841BDE-2631-4862-93C1-B96BDC8920CE

Q24633911-1D0C91E0-E447-442B-A2F8-6AE10A684607

Q24633911-B06ADB1F-6C62-4954-B70E-E47F18D4D4DB

Q24633911-E5720477-53F6-434C-8CF8-EB215043FA58

Q24633911-FEACFC3F-484C-4C8B-8EC6-7769A1782C0E

P2860

Q24633911-04E905EC-C9C3-4066-8856-F19C43A1ACE0

Q24633911-088B178A-C104-4B4B-8B91-C95FDD8757C4

Q24633911-0E46A847-18BC-45BC-8CA1-DDD7C6826640

Q24633911-1251F049-8F3C-4826-949E-8F892F13CA89

Q24633911-1492980D-3030-497B-9286-F94C3CAEEB0D

Q24633911-14A0A8CA-D16D-4CDF-8BFF-3D95AF266F65

Q24633911-16CD8901-263B-4EC0-9617-A27D763B2412

Q24633911-1AE8E955-97FD-4E25-9F29-CA032DA6F567

Q24633911-2183E918-812E-4E37-AF6B-23078F485571

Q24633911-246F405C-A5BA-4446-AED3-54FB50A577BF

P304

Q24633911-40A4EEEE-7226-40DE-B3D6-0896D4390553

P31

Q24633911-7338F533-E42B-4318-B2E9-F5062FE99B5A

P356

Q24633911-A2F8B4D8-613F-4B60-902D-E1CCB4C9A321

P407

Q24633911-0F278141-6A5C-488B-9D81-1C7BA82C81E7

P433

Q24633911-4DF931F6-E18F-44C3-8FD1-7ABE9BE943A6

P478

Q24633911-4B724A22-B7C0-4E82-834A-7921E801F1A2

P577

Q24633911-0892D1A6-DAA0-479D-892F-B65E99B4D67D

P698

Q24633911-309DB44E-5B5C-4705-98CB-BFD48955CB97

P921

Q24633911-301FA028-B54D-4515-8C56-C5B17721662F

P932

Q24633911-6B2A4652-6D3D-4CF4-B2FA-23B13BFE0ACD

P356

P1433

Journal of Alzheimer's Disease

P1476

Selective interaction of lanso ...... agnosis of Alzheimer's disease

@en

P2093

Iván N Saavedra

http://www.w3.org/2001/XMLSchema#string

Jans Alzate-Morales

http://www.w3.org/2001/XMLSchema#string

Leonel E Rojo

http://www.w3.org/2001/XMLSchema#string

Peter Davies

http://www.w3.org/2001/XMLSchema#string

Ricardo B Maccioni

http://www.w3.org/2001/XMLSchema#string

P2860

Alzheimer Disease in the US Population

Hyperphosphorylation induces self-assembly of tau into tangles of paired helical filaments/straight filaments

X-ray structure of the PHF core C-terminus: insight into the folding of the intrinsically disordered protein tau in Alzheimer's disease

Role of the JAKs/STATs pathway in the intracellular calcium changes induced by interleukin-6 in hippocampal neurons

Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology

Microtubule-associated protein tau (tau) is a major antigenic component of paired helical filaments in Alzheimer disease

Modification of tau to an Alzheimer's type protein interferes with its interaction with microtubules.

Variations among non-sedating antihistamines: are there real differences?

The molecular bases of Alzheimer's disease and other neurodegenerative disorders.

Anomalously phosphorylated tau and Abeta fragments in the CSF correlates with cognitive impairment in MCI subjects.

P304

573-89

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3233/JAD-2010-1262

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

19

http://www.w3.org/2001/XMLSchema#string

P577

2010-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20110603

http://www.w3.org/2001/XMLSchema#string

P921

Alzheimer's disease

P932

2951486

http://www.w3.org/2001/XMLSchema#string